Cat. No.: HY-10984

Pomalidomide

(Synonyms: CC-4047)

35 Cited Publications

Avis client

Based on 35 publication(s) in Google Scholar

Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.88%
CAS No.: 19171-19-8
Formule: C₁₃H₁₁N₃O₄
Masse moléculaire:273.24

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Pomalidomide Chemical Structure

CAS No.: 19171-19-8

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (35)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target^[5]

Cereblon

IKZF1

IKZF3

Voir tous les produits spécifiques à Isoform Ligands for E3 Ligase :

Voir tous les produits spécifiques à Isoform IKZF Family :

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	>10 μM Compound: POM	Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33256948]
A549	IC₅₀	>33.3 μM Compound: Poma	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay	[PMID: 39089850]
B16-F10	IC₅₀	>10 μM Compound: POM	Cytotoxicity against mouse B16F10 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against mouse B16F10 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33256948]
BXPC-3	IC₅₀	≤30 μM Compound: POM	Antiproliferative activity against human BxPC-3 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Antiproliferative activity against human BxPC-3 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 33506674]
HCT-116	IC₅₀	>50 μM Compound: Pomalidomide	Antiproliferative activity against human HCT-116 cells expressing wildtype ATM incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HCT-116 cells expressing wildtype ATM incubated for 72 hrs by CCK8 assay	[PMID: 38325007]
HCT-116	IC₅₀	>33.3 μM Compound: Poma	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay	[PMID: 39089850]
HeLa	IC₅₀	1.27 μM Compound: actimid	Inhibition of IL-1-alpha-induced NF-kappaB activation in HeLa cells assessed as blocking of p50/p65 nuclear translocation Inhibition of IL-1-alpha-induced NF-kappaB activation in HeLa cells assessed as blocking of p50/p65 nuclear translocation	[PMID: 17845850]
JeKo-1	IC₅₀	2617.33 nM Compound: Pomalidomide	Antiproliferative activity against human Jeko-1 cells assessed as cell viability measured after 7 days by CCK-8 assay Antiproliferative activity against human Jeko-1 cells assessed as cell viability measured after 7 days by CCK-8 assay	[PMID: 35635954]
JeKo-1	IC₅₀	>20000 nM Compound: Pomalidomide	Antiproliferative activity against human Jeko-1 cells expressing CRBN-knockout assessed as cell viability measured after 7 days by CCK-8 assay Antiproliferative activity against human Jeko-1 cells expressing CRBN-knockout assessed as cell viability measured after 7 days by CCK-8 assay	[PMID: 35635954]
Jurkat	IC₅₀	>33.3 μM Compound: Poma	Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay	[PMID: 39089850]
K562	IC₅₀	>10 μM Compound: Pomalidomide	Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay	[PMID: 34217059]
K562	IC₅₀	>10 μM Compound: Pomalidomide	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 2 days by CCK8 assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 2 days by CCK8 assay	[PMID: 36306539]
KARPAS-299	IC₅₀	>10 μM Compound: pomalidomide	Antiproliferative activity against human KARPAS-299 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human KARPAS-299 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34176264]
LoVo	IC₅₀	>50 μM Compound: Pomalidomide	Antiproliferative activity against ATM deficient human LoVo cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against ATM deficient human LoVo cells incubated for 72 hrs by CCK8 assay	[PMID: 38325007]
LP-1	GI₅₀	>10 μM Compound: pom	Antiproliferative activity against human LP-1 cells assessed as growth inhibition incubated for 3 days by fluorescence based assay Antiproliferative activity against human LP-1 cells assessed as growth inhibition incubated for 3 days by fluorescence based assay	[PMID: 38505842]
MCF7	IC₅₀	>100 μM Compound: Pomalidomide	Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 34864330]
MCF7	IC₅₀	17 μM Compound: Pomalidomide	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 37229829]
MCF7	IC₅₀	>100 μM Compound: Poma	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37619298]
MDA-MB-231	IC₅₀	>100 μM Compound: Pomalidomide	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 34864330]
MDA-MB-231	IC₅₀	>100 μM Compound: Poma	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37619298]
MDA-MB-468	IC₅₀	>100 μM Compound: Poma	Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37619298]
MIA PaCa-2	IC₅₀	≤30 μM Compound: POM	Antiproliferative activity against human MIA PaCa-2 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Antiproliferative activity against human MIA PaCa-2 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 33506674]
MM1.S	IC₅₀	21.93 nM Compound: Pomalidomide	Antiproliferative activity against human MM1.S cells assessed as cell viability measured after 7 days by CCK-8 assay Antiproliferative activity against human MM1.S cells assessed as cell viability measured after 7 days by CCK-8 assay	[PMID: 35635954]
MM1.S	IC₅₀	837.8 nM Compound: Pomalidomide	Antiproliferative activity against human MM1.S cells assessed as cell viability measured after 3 days by CCK-8 assay Antiproliferative activity against human MM1.S cells assessed as cell viability measured after 3 days by CCK-8 assay	[PMID: 35635954]
MX1	IC₅₀	>100 μM Compound: Poma	Antiproliferative activity against human MX1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human MX1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37619298]
NAMALVA	IC₅₀	0.03 μM Compound: 2	Antiproliferative activity against human NAMALWA cells assessed as inhibition of [3H]thymidine incorporation after 72 hrs by scintillation counting Antiproliferative activity against human NAMALWA cells assessed as inhibition of [3H]thymidine incorporation after 72 hrs by scintillation counting	[PMID: 23168019]
NCI-H929	CC₅₀	0.035 μM Compound: Pomalidomide	Antiproliferative activity against human NCI-H929 cells after 72 hrs by WST-1 assay Antiproliferative activity against human NCI-H929 cells after 72 hrs by WST-1 assay	[PMID: 30684871]
OCI-Ly10	IC₅₀	1.4 μM Compound: 2	Antiproliferative activity against human OCI-Ly10 cells measured after 4 days by CellTiter-Glo Luminescent Cell Viability Assay Antiproliferative activity against human OCI-Ly10 cells measured after 4 days by CellTiter-Glo Luminescent Cell Viability Assay	[PMID: 38920289]
PBMC	IC₅₀	13 nM Compound: 5a	Inhibition of lipopolysaccharide stimulated TNF-alpha release in human PBMC Inhibition of lipopolysaccharide stimulated TNF-alpha release in human PBMC	[PMID: 10386948]
PBMC	IC₅₀	0.013 μM Compound: 2	Inhibition of TNF-alpha production in LPS-stimulated human PBMC preincubated for 1 hr before LPS challenge measured after 28 to 20 hrs by ELISA Inhibition of TNF-alpha production in LPS-stimulated human PBMC preincubated for 1 hr before LPS challenge measured after 28 to 20 hrs by ELISA	[PMID: 23168019]
T-cell	EC₅₀	0.008 μM Compound: 2	Inhibition of IL-2 production in human T cells measured after 2 to 3 days by ELISA Inhibition of IL-2 production in human T cells measured after 2 to 3 days by ELISA	[PMID: 23168019]
THP-1	IC₅₀	>33.3 μM Compound: Poma	Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay	[PMID: 39089850]
TMD8	IC₅₀	187 nM Compound: Pomalidomide	Cytotoxicity against human TMD8 cells incubated for 48 hrs by celltitre glo 2.0 assay Cytotoxicity against human TMD8 cells incubated for 48 hrs by celltitre glo 2.0 assay	[PMID: 37195170]

In Vitro

Pomalidomide also inhibits Whole Blood TNF-α with IC₅₀ of 25 nM^[1]. Exposure of lymphoma cells to Pomalidomide (CC-4047) leads to 40% decrease in cell proliferation when compared with vehicle-treated controls. Pomalidomide inhibits by 40% the DNA synthesis of Raji cells (P=0.036)^[2]. In both CD4⁺ and CD8⁺ cells, Pomalidomide (CC-4047) is the most potent IL-2-elevator, followed by CC-6032 and CC-5013. Pomalidomide is significantly more potent than CC-5013 at elevating IL-2, IL-5, and IL-10, and slightly more potent than CC-5013 at elevating IFN-γ^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The administration of Pomalidomide (CC-4047) for two consecutive days before mAb therapy enhances the antitumor activity of Rituximab and doubled the median survival of lymphoma-bearing mice. Statistically, significant differences are observed between animals treated with Rituximab versus Pomalidomide+Rituximab. The median survival time of animals treated with Pomalidomide and Rituximab is longer (median survival, 74 days; 95% CI, 70-78) than those treated with Rituximab monotherapy (median survival, 38 days; 95% CI, 26-50; log-rank test, P=0.002). The administration of CC-5013 or Pomalidomide for two consecutive days leads to a significant increase in the number of circulating NK cells as shown by flow cytometry analysis, in lymphoma-bearing SCID mice^[2]. Following a 50 mg/kg PO administration of Pomalidomide (POM) to rats, unbound concentrations in blood reach a C_max value of 1100±82 ng/mL at 4.6±2.4 hours, with a concomitant AUC_(0-10) value of 6800±2000 ng hr/mL. Unbound POM in the brain, however, has a C_max value of 430±63 ng/mL at 4.1±1.5 hours and an AUC_(0-10) value of 2700±740 ng hr/mL, giving an unbound AUC_brain to AUC_blood ratio of 0.39±0.03. These values are consistent with excellent blood-brain-barrier penetration. The results obtained in this study are consistent with those seen in a concurrent study looking at whole brain POM content following its oral administration to mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 19171-19-8
Appearance Solid
Masse moléculaire 273.24
Formule C₁₃H₁₁N₃O₄
Color Light yellow to yellow
SMILES

O=C1N(C(C2=C1C=CC=C2N)=O)C(C(N3)=O)CCC3=O
Synonyms

CC-4047
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (35)

All WB

Sort by:

Journal Impact Factor

Cancer Cell

High-performance multiplex drug-gated CAR circuits. [Abstract]

2022 Nov 14;40(11):1294-1305.e4. PMID: 36084652
Cell

Structural basis and regulation of the reductive stress response. [Abstract]

2021 Oct 14;184(21):5375-5390.e16. PMID: 34562363
Nat Cancer

IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia. [Abstract]

2022 May;3(5):595-613. PMID: 35534777

Pomalidomide purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2022 May;3(5):595-613. [Abstract]

Western blot analysis for IKAROS, CK1α and MENIN protein following treatment of MV4;11 human MLL-r AML cell line for 5 hours with increasing doses of Thalidomide, lenalidomide, Pomalidomide and iberdomide (10,100, 1000 nM), using ACTIN as a loading control.
Cancer Res

CFT1946 is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader that Overcomes BRAF Inhibitor Resistance. [Abstract]

2025 Oct 28. PMID: 41150906
Nat Commun

Therapeutic targeting nudix hydrolase 1 creates a MYC-driven metabolic vulnerability. [Abstract]

2024 Mar 16;15(1):2377. PMID: 38493213
Nat Commun

Functional genomics uncovers the transcription factor BNC2 as required for myofibroblastic activation in fibrosis. [Abstract]

2022 Sep 10;13(1):5324. PMID: 36088459

Pomalidomide purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Sep 10;13(1):5324. [Abstract]

Western immunoassays used to monitor changes in BNC2 levels in LX2 cells treated with 1 μM pomalidomide (Pom.), thalidomide (Thal.), CC-885, Iberdomide (Iber.) or vehicle for 24 h.
Nat Commun

pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase. [Abstract]

2017 May 22;8:15398. PMID: 28530236

Pomalidomide purchased from MedChemExpress. Usage Cited in: Nat Commun. 2017 May 22;8:15398. [Abstract]

NUDT1 immunoblots using SF188 cells pretreated with pomalidomide (10 µM) for 2 h, and then subjected to an additional 6 h treatment with DMSO or LC-1-40 (50 nM).
Acta Pharm Sin B

2026 Feb 10.
Biomaterials

Automated discovery of nanomaterials via drug aggregation induced emission. [Abstract]

2022 Oct:289:121800. PMID: 36166893
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
J Transl Med

Doxorubicin synergizes bortezomib-induced multiple myeloma cell death by inhibiting aggresome formation and augmenting endoplasmic reticulum/Golgi stress and apoptosis. [Abstract]

2024 Dec 3;22(1):1095. PMID: 39623468
J Med Chem

Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader. [Abstract]

2024 Oct 24;67(20):18247-18264. PMID: 39388374
Elife

Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. [Abstract]

2018 Aug 1;7:e38430. PMID: 30067223

Pomalidomide purchased from MedChemExpress. Usage Cited in: Elife. 2018 Aug 1;7:e38430. [Abstract]

H9 hESC are treated with increasing concentrations of Thalidomide, Lenalidomide, Pomalidomide, or DMSO as a control. Following 24 h of incubation, SALL4 and GAPDH protein levels are assessed by western blot analysis.
Mol Ther Oncol

Dual CARM1-and IKZF3-targeting: A novel approach to multiple myeloma therapy synergy between CARM1 inhibition and IMiDs. [Abstract]

2025 Feb 20;33(1):200952. PMID: 40123976
Drug Des Devel Ther

2026 Jan 22;20:1-21.
Eur J Pharmacol

Doxorubicin-mediated retardation of aggresome formation enhances Carfilzomib-induced cell death synergistically by augmenting ER stress and proapoptotic signaling. [Abstract]

2025 Dec 5:1008:178303. PMID: 41183585
Int Immunopharmacol

Pomalidomide promotes macrophage control of Mycobacterium tuberculosis via enhancing HDAC6-mediated autophagy. [Abstract]

2025 May 14:158:114831. PMID: 40373598
Cancers (Basel)

Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma. [Abstract]

2024 Mar 28;16(7):1319. PMID: 38610997
Structure

CAND1 and CAND2 drive CUL4 substrate receptor exchange with largely comparable biochemical efficiency, unlike their relative effects on CUL1. [Abstract]

2026 Mar 20:S0969-2126(26)00056-0. PMID: 41864201
iScience

iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells. [Abstract]

2023 Jun 7;26(7):107059. PMID: 37360684
Clin Exp Immunol

Bone marrow-derived mesenchymal stem cells inhibit CD8+ T cell immune responses via PD-1/PD-L1 pathway in multiple myeloma. [Abstract]

2021 Jul;205(1):53-62. PMID: 33735518
Stem Cells Dev

The Supportive Role of Lymph Node Mesenchymal Stromal Cells in Follicular Lymphoma Involves the PITX1-hTERT-Podoplanin Axis. [Abstract]

2025 Mar 25. PMID: 40130551
Gen Comp Endocrinol

Tumour necrosis factor-α inhibits hepatic lipid deposition through GSK-3β/β-catenin signaling in juvenile turbot (Scophthalmus maximus L.). [Abstract]

2015 Dec 30;228:1-8. PMID: 26747182

Pomalidomide purchased from MedChemExpress. Usage Cited in: Gen Comp Endocrinol. 2015 Dec 30;228:1-8. [Abstract]

TNFα significantly inhibits the mRNA and protein expression of GSK-3β, while POM significantly induces the mRNA and protein expression of GSK-3β (A). The mRNA and protein expression of β-catenin is significantly induced by TNFα, but significantly inhibited by POM (B). The protein expression of PPARγ and C/EBPα is significantly inhibited by TNFα, while significantly induced by POM treatment (C and D).
bioRxiv

A bulk cell heterozygous knock-in strategy for targeted protein degradation. [Abstract]

2026 May 21:2026.05.19.726384. PMID: 42239119
bioRxiv

Regulation of BCL11A DNA binding and expression in human erythrocyte precursor HUDEP-2 cells. [Abstract]

2026 Feb 8:2026.02.06.704516. PMID: 41822826
Charles University

2026.
Chemrxiv

2025 Nov 17.
Harvard University

2025.
bioRxiv

2025 Jun 19.
bioRxiv

2025 January 08.
Patent

US20240245677A1.
University of Colorado Denver

2024.
University of Colorado Denver

2024.
bioRxiv

2024 Jan 28.
Masaryk University

2014.

Solvant et solubilité

In Vitro:

DMSO : 50 mg/mL (182.99 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.6598 mL

18.2989 mL

36.5979 mL

5 mM

0.7320 mL

3.6598 mL

7.3196 mL

10 mM

0.3660 mL

1.8299 mL

3.6598 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/0.5% Tween-80 in Saline water

Solubility: 10 mg/mL (36.60 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Cell Assay^[2]

Lymphoma cell lines are placed in 96-well plates (1×10⁵ cells per well) and exposed to escalating concentrations of CC-5013, Pomalidomide (2.5, 5, 10, 20, and 40 μg/mL), or vehicle control single agents or in combination with Rituximab or Trastuzumab (isotype), at a final antibody concentration of 10 μg/mL. The final concentration is adjusted to 200 μL with 10% RPMI. The cell lines are incubated at 37°C and 5% CO₂ for 24 and 48 hours. Following 24 or 48 hours, 1 μCi per well of [³H]-thymidine is added and cells are incubated for 18 hours more. Cells are then harvested using the Harvest system into the 96-well glass filters and [³H]-thymidine uptake is measured using an automated scintillation counter. Each experiment is done in triplicate at three different times; results are presented as the mean of counts per minute (cpm) at 24 and 48 hours±SD^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]^[4]

Mice^[2]
Six- to 8-week-old SCID mice are used for this purpose. On day 0, all the animals receive 1×10⁶ Raji cells via tail vein injection. After 72 hours of tumor engraftment, the animals are divided into seven cohorts. The first cohort (group A) serve as control and receive no treatment. Groups B and C consist of animals treated with either CC-5013 (0.5 mg/kg) or Pomalidomide (0.5 mg/kg) given i.p. on days +3, +4, +8, +9, +13, +14, +18, and +19. Groups D and E are treated with Rituximab or Trastuzumab (isotype control) monotherapy given via tail vein injection at 10 mg/kg on days +5, +10, +15, and +20. Finally, groups F and G consist of animals treated with Rituximab in combination with CC-5013 (group E) or Pomalidomide (group G). IMiDs are given i.p. for two consecutive days before each dose of Rituximab. After completion of therapy, animals are observed for a period of 90 days. The end point of the study is survival defined as the time for the development of limb paralysis. Animals that reach the end point or survived after 3 months of observation are sacrificed by cervical dislocation. Pathologic examination of all organs (liver, lung, and brain) is done to detect any residual disease. The experiments are repeated in three separate occasions.
Rats^[4]
A total of 3 male CD-IGS rats are used. Pomalidomide is administered as a single PO administration via the stomach cannula, at 50 mg/kg (5 mL/kg) in a 0.5% carboxymethylcellulose/0.25% Tween 80 suspension formulation. Microdialysate is collected in a cooling fraction collector, set at 4°C at intervals of 25 minutes for 10 hours after dosing. To calculate AUC, the corrected concentration of each sample is multiplied by the interval over which the sample is collected; in this case 25 minutes, and divided by 60 minutes per hour. The sum of these values represented the total AUC value over the specified time range. To generate graphs, the concentration at each time point is plotted at the mid-point of each collection interval. Microdialysates are collected at the specified time points and analyzed for Pomalidomide concentration using a LC-MS/MS assay, within 12 hours.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (286 KB)
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Korean - KR (418 KB)
- Portuguese - PT (418 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Zhu YX, et al. Molecular mechanism of action of the immune-modulatory drugs, thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013 Apr;54(4):683-7. [Content Brief]

[2]. Hernandez-Ilizaliturri FJ1, et al. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005 Aug 15;11(16):5984-92. [Content Brief]

[3]. Schafer PH, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther. 2003 Jun;305(3):1222-32. [Content Brief]

[4]. Li Z, et al. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. PLoS One. 2013 Aug 5;8(8):e71754. [Content Brief]

[5]. Lu J, et al. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. Chem Biol. 2015 Jun 18;22(6):755-63. [Content Brief]

[6]. Liu D, et al. Tumour necrosis factor-α inhibits hepatic lipid deposition through GSK-3β/β-catenin signaling in juvenile turbot (Scophthalmus maximus L.). Gen Comp Endocrinol. 2016 Mar 1;228:1-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.6598 mL	18.2989 mL	36.5979 mL	91.4947 mL
	5 mM	0.7320 mL	3.6598 mL	7.3196 mL	18.2989 mL
	10 mM	0.3660 mL	1.8299 mL	3.6598 mL	9.1495 mL
	15 mM	0.2440 mL	1.2199 mL	2.4399 mL	6.0996 mL
	20 mM	0.1830 mL	0.9149 mL	1.8299 mL	4.5747 mL
	25 mM	0.1464 mL	0.7320 mL	1.4639 mL	3.6598 mL
	30 mM	0.1220 mL	0.6100 mL	1.2199 mL	3.0498 mL
	40 mM	0.0915 mL	0.4575 mL	0.9149 mL	2.2874 mL
	50 mM	0.0732 mL	0.3660 mL	0.7320 mL	1.8299 mL
	60 mM	0.0610 mL	0.3050 mL	0.6100 mL	1.5249 mL
	80 mM	0.0457 mL	0.2287 mL	0.4575 mL	1.1437 mL
	100 mM	0.0366 mL	0.1830 mL	0.3660 mL	0.9149 mL

Keywords

Pomalidomide

35 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Pomalidomide

Apoptosis Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Drug Repurposing Compound Library

Ubiquitination Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Rare Diseases Drug Library

Chemotherapy Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

E3 Ligase Ligand Library

Molecular Glue Compound Library

Off-patent Drug Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

Cardiotoxic Compound Library

Posttranslational Modification Library

Nephrotoxicity Compound Library

RNA Binding Bioactive Compound Library

Classic FDA-Approved Drug Library

3D Diverse Fragment Library

MCE Kinase Hinge Binder Fragment Library

Molecular Glue-like Compound Library

Publications Citing Use of MedChemExpress (MCE) Pomalidomide

Voir tous les produits spécifiques à Isoform Ligands for E3 Ligase

Voir tous les produits spécifiques à Isoform IKZF Family

Activité biologique

Chemical Information

Publications (35)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Pomalidomide Related Classifications

HY-10984 Related Classifications